Certolizumab and adalimumab are the two most noteworthy biologics behind this recent rise in biologic treatments for Crohn’s patients in remission, but infliximab remains the most prevalent biologic treatment for Crohn’s Disease on the market.
More Articles on Gastroenterology:
Columbus Regional Health Opens $3.8M Endoscopy Center
How Much do Gastroenterologist Make? 27 Statistics
Swallow Solutions Launches Dysphagia Treatment Device
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
